TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
A phase 1/2 trial of TQB2922 in colorectal cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
Overview
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07044908 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 72 participants planned, started 2025-07-30 and due to reach its primary completion in 2026-07. Interventions recorded: TQB2922 injection ± TAS-102 tablets, TQB2922 injection+TAS-102 tablets ± Bevacizumab. Conditions listed: RAS/BRAF Wild Type Colorectal Cancer. No results are recorded here; the registry entry is the source.